Janssen Shares Erdafitinib Combo Therapy Data In Bladder Cancer

Janssen, a unit of Johnson & Johnson JNJ, announced results from the Phase 1b/2 NORSE study evaluating Balversa (erdafitinib) plus cetrelimab combination.
The trial included patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin.
The results were highlighted at the European Society for Medical Oncology (ESMO21) Annual Congress 2021.
The investigator-assessed objective response rate (ORR) in 19 patients treated with Balversa plus cetrelimab was 68%, of which 21% were complete responses (CR), and 47% were partial responses (PR).
The disease control rate (DCR) was 90%.
The ORR in 18 patients treated with Balversa monotherapy was 33%, in which one patient showed a CR and 28% (n=5) were partial responses.
The DCR was 100%.
Price Action: JNJ shares are down 0.61% at $164.22 during the market session on the last check Friday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

Overview Rating:

Speculative

0100